Gianni Chessari,Ian R. Hardcastle,Jong Sook Ahn,Burcu Anil,Elizabeth Anscombe,Ruth H. Bawn,Luke D. Bevan,Timothy J. Blackburn,Ildiko Buck,Celine Cano,Benoit Carbain,Juan Castro,Ben Cons,Sarah J. Cully,Jane A. Endicott,Lynsey Fazal,Bernard T. Golding,Roger J. Griffin,Karen Haggerty,Suzannah J. Harnor,Keisha Hearn,Stephen Hobson,Rhian S. Holvey,Steven Howard,Claire E. Jennings,Christopher N. Johnson,John Lunec,Duncan C. Miller,David R. Newell,Martin E. M. Noble,Judith Reeks,Charlotte H. Revill,Christiane Riedinger,Jeffrey D. St. Denis,Emiliano Tamanini,Huw Thomas,Neil T. Thompson,Mladen Vinković,Stephen R. Wedge,Pamela A. Williams,Nicola E. Wilsher,Bian Zhang,Yan Zhao,Mladen Vinković

Abstract:Inhibition of murine double minute 2 (MDM2)-p53 protein–protein interaction with small molecules has been shown to reactivate p53 and inhibit tumor growth. Here, we describe rational, structure-guided, design of novel isoindolinone-based MDM2 inhibitors. MDM2 X-ray crystallography, quantum mechanics ligand-based design, and metabolite identification all contributed toward the discovery of potent in vitro and in vivo inhibitors of the MDM2-p53 interaction with representative compounds inducing cytostasis in an SJSA-1 osteosarcoma xenograft model following once-daily oral administration.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02188?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02188</a>.Molecular formula string (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_001.csv">CSV</a>)Model of the X-ray crystal structure of MDM2 with compound 4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_002.cif">CIF</a>)Structure factors of the X-ray crystal structure of MDM2 with compound 4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_003.cif">CIF</a>)Additional experimental details for compounds not included in the main section and analytical data for all compounds and intermediates; NMR studies on 5; X-ray structure tables; and computational chemistry (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_004.pdf">PDF</a>)This article has not yet been cited by other publications.

Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2

Synthesis and Structure-Activity Relationship Studies of LLY-507 Analogues As SMYD2 Inhibitors.

Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2

Discovery of Novel Lysine Methyltransferase (SMYD3) Inhibitors by Utilizing 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation

Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies

Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)

Protein Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and Structure Activity Relationships of 2,4-Diamino-7-aminoalkoxy-quinazolines.

Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A

Optimization and Biological Evaluation of Novel 1H-Pyrrolo[2,3-c]pyridin Derivatives As Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia

Discovery of Natural Product-Like Spirooxindole Derivatives As Highly Potent and Selective LSD1/KDM1A Inhibitors for AML Treatment.

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives As Novel Inhibitors of P53-Mdm2 Protein-Protein Interaction.

Development of the Triazole-Fused Pyrimidine Derivatives As Highly Potent and Reversible Inhibitors of Histone Lysine Specific Demethylase 1 (LSD1/KDM1A)

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy

Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy

Discovery of (S)-N-(2-amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6h)-yl)ethyl)benzamide As Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate.

Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.

Discovery of novel PRMT5 inhibitors bearing a methylpiperazinyl moiety.

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas